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Abstract
In the latest update of the European Society of Cardiology (ESC) guidelines for the management of infective
endocarditis (IE), imaging is positioned at the centre of the diagnostic work-up so that an early and accurate
diagnosis can be reached. Besides echocardiography, contrast-enhanced CT (ce-CT), radiolabelled leucocyte (white
blood cell, WBC) SPECT/CT and [18F]FDG PET/CT are included as diagnostic tools in the diagnostic flow chart for
IE. Following the clinical guidelines that provided a straightforward message on the role of multimodality imaging,
we believe that it is highly relevant to produce specific recommendations on nuclear multimodality imaging in IE
and cardiac implantable electronic device infections. In these procedural recommendations we therefore describe in
detail the technical and practical aspects of WBC SPECT/CT and [18F]FDG PET/CT, including ce-CT acquisition
Preamble The European Association of Nuclear Medicine (EANM) is a
professional nonprofit medical association that facilitates communication
worldwide among individuals pursuing clinical and research excellence
in nuclear medicine. The EANM was founded in 1985.
These recommendations are intended to assist practitioners in providing
appropriate nuclear medicine care for patients. They are not inflexible
rules or requirements of practice and are not intended, nor should they
be used, to establish a legal standard of care.
The ultimate judgment regarding the propriety of any specific procedure
or course of action must be made by medical professionals taking into
account the unique circumstances of each case. Thus, there is no impli-
cation that an approach differing from the recommendations, standing
alone, is below the standard of care. To the contrary, a conscientious
practitioner may responsibly adopt a course of action different from that
set out in the guidelines when, in the reasonable judgment of the practi-
tioner, such course of action is indicated by the condition of the patient,
the limitations of available resources or advances in knowledge or tech-
nology subsequent to publication of the recommendations.
The practice of medicine involves not only the science but also the art of
dealing with the prevention, diagnosis, alleviation and treatment of dis-
ease. The variety and complexity of human conditions make it impossible
to always reach the most appropriate diagnosis or to predict with certainty
a particular response to treatment. Therefore, it should be recognized that
adherence to these recommendations will not ensure an accurate diagno-
sis or a successful outcome. All that should be expected is that the prac-
titioner will follow a reasonable course of action based on current knowl-
edge, available resources and the needs of the patient to deliver effective
and safe medical care. The sole purpose of these recommendations is to
assist practitioners in achieving this objective.
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protocols. We also discuss the advantages and limitations of each procedure, specific pitfalls when interpreting
images, and the most important results from the literature, and also provide recommendations on the appropriate
use of multimodality imaging.
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Introduction
Over the last decades, there have been a series of tech-
nology improvements that have significantly changed
the role of clinical imaging in healthcare. Evolving tech-
nologies such as multimodality imaging have gained a
central key role in the evaluation of several disease
entities. Infectious endocarditis (IE), on both native
valve (NVE) and prosthetic valve (PVE), and cardiovas-
cular implantable electronic device (CIED) infections
are examples of such diseases in which multimodality
imaging is used effectively in decision-making.
Extensive clinical use of radiolabelled leucocyte (white
blood cell, WBC) SPECT/CT and [18F]FDG PET/CT in the
imaging of IE has provided robust evidence of a major impact
on patient management in terms of early diagnosis and the
selection of optimal treatment strategies [1]. Therefore, in
the latest update of the European Society of Cardiology
(ESC) guidelines for the management of IE [2] both tech-
niques are included as diagnostic tools in the diagnostic flow
chart for PVE in particular. In these guidelines, imaging is a
fundamental backbone of the diagnostic strategy, due to the
concept that IE, rather than a single disease, may present with
very different clinical patterns depending on the first organ
involved, the underlying cardiac disease (if any), the microor-
ganism involved, the presence or absence of complications,
and the patient’s characteristics. Therefore, imaging specialists
with a high level of expertise need to participate in a multidis-
ciplinary team together with practitioners from several other
specialties, including cardiologists, microbiologists, clinicians
and surgeons.
Following the clinical guidelines that provide a
straightforward message on the role of multimodality
imaging, we believe that it is highly relevant to produce
specific recommendations on nuclear and multimodality
imaging in IE and CIED infections. Therefore, in these
procedural recommendations, we describe in detail the
technical and practical aspects of WBC SPECT/CT and
[18F]FDG PET/CT, including contrast-enhanced CT (ce-
CT) acquisition protocols. We also discuss the advan-
tages and limitations of each procedure, specific pitfalls
when interpreting images, the most important results
from the literature and recommendations on the appro-
priate use of multimodality imaging.
Definition and clinical challenges in IE
and CIED infections
IE is a life-threatening disease associated with a high
mortality rate, difficult diagnosis and controversial man-
agement [3, 4]. The clinical history of IE is highly
variable and depends on the causative microorganism,
the presence or absence of preexisting cardiac disease,
the presence or absence of prosthetic valves or cardiac
devices, and the mode of presentation. IE may present
as an acute, rapidly progressive infection, but also as a
subacute or chronic disease, and should be suspected in
a variety of very different clinical scenarios [2].
Echocardiography and blood cultures are the cornerstone
of IE diagnosis. Three echocardiographic findings are consid-
ered as major criteria in the diagnosis of IE: vegetation, ab-
scess or pseudoaneurysm, and new dehiscence of a prosthetic
valve. However, the diagnostic accuracy of echocardiography
may be challenging in PVE and intracardiac device infection,
even with the use of transoesophageal echocardiography
(TOE). Similarly, false diagnosis of IEmay occur, and in some
instances it may be difficult to differentiate vegetations from
thrombi or other noninfective valvular lesions. Therefore, the
results of the echocardiographic study must be interpreted
with caution, taking into account the patient’s clinical presen-
tation and the likelihood of IE.
CIED infection is a dreadful complication of cardiac device
implantation with a high mortality rate [5], and is increasingly
observed in elderly patients [6]. The reported incidence of
permanent pacemaker infection varies widely among studies
[7]. A distinction should be made between local device infec-
tion and cardiac device-related IE (CDRIE). Local device in-
fection is defined as an infection limited to the pocket of the
cardiac device and/or extravascular lead infection, while
CDRIE is defined as an infection extending to the intravascu-
lar and/or intracardiac lead, cardiac valve leaflets, or endocar-
dial surface. Both diagnosis and therapeutic strategy are par-
ticularly challenging in these patients [2].
As in NVE, echocardiography plays a key role in CDRIE
and is helpful in the diagnosis of lead vegetations and tricuspid
involvement, quantification of tricuspid regurgitation, sizing
of vegetations, and follow-up after lead extraction [2].
However, false-negative and false-positive echo studies are
not rare, and the Duke criteria are difficult to apply in these
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patients because of lower sensitivity [5], even when the mod-
ified Duke criteria are used.
Because of the frequently difficult diagnosis of the disease,
and because of some limitations of echocardiography, partic-
ularly in patients with PVE and CDRIE, other imaging tech-
niques have recently been applied, including nuclear tech-
niques and ce-CT [8].
Summary of the 2015 ESC guidelines
for the management of infective endocarditis
The recently published 2015 ESC guidelines on the manage-
ment of IE [2] propose important new features, including the
need for a collaborative approach (the ‘Endocarditis Team’),
the emergence of nuclear imaging techniques in the early di-
agnosis of IE, and the refinement of surgical indications.
The Endocarditis Team
An interdisciplinary approach is required for the successful
treatment of patients with IE and CIED infection. This team
approach involves specialists in imaging, cardiologists, cardi-
ac surgeons, specialists in infectious disease, and others. This
multidisciplinary approach has already shown significant ad-
vantages in the management of valvular heart disease (the
‘Heart Valve Clinic’), particularly in the selection of patients
for transcatheter aortic valve implantation procedures (‘Heart
Team’ approach) [9]. Such a team approach has been recom-
mended recently as class IB in the 2014 American Heart
Association/American College of Cardiology (AHA/ACC)
guidelines for the management of patients with valvular heart
disease [10] as well as a class IIa, level B recommendation in
the 2015 ESC guidelines [2]. In patients with IE, a team ap-
proach has been shown to significantly reduce 1-year mortal-
ity [11]. In the setting of the Endocarditis Team, a new entity,
the ‘imaging specialist’, plays a fundamental role: specialists
in echocardiography, but also experts in nuclear medicine im-
aging, cardiac CT, and magnetic resonance imaging (MRI) are
increasingly included in the team. Decisions about how to
diagnose, manage, treat and follow-up patients should be tak-
en in reference centres based on consensus decisions by the
Endocarditis Team (Table 1).
Cardiac imaging in the early diagnosis of IE
Early diagnosis of IE is a major challenge. In 2000, the mod-
ified Duke criteria were recommended for diagnostic classifi-
cation, and are mainly based upon echocardiography and
blood culture results [12]. This classification has a sensitivity
of approximately 80% for the diagnosis of IE [13]. However,
the modified Duke criteria have a lower diagnostic accuracy in
clinical practice, especially in patients with PVE and CDRIE,
in up to 30% of whom echocardiography is normal or incon-
clusive, and in patients with blood culture-negative IE. Recent
advances in imaging techniques, including cardiac/whole-
body CT, cerebral MRI, [18F]FDG PET/CT and radiolabelled
WBC SPECT/CT, have resulted in improved identification of
endocardial involvement and extracardiac complications of IE
[8]. Recent studies have demonstrated that the addition of a
Table 1 Characteristics of the Endocarditis Team
When to refer a patient with IE to an Endocarditis Team in a reference centre
Patients with complicated IE, i.e. endocarditis with HF, abscess, or embolic or neurological complication or CHD, should be referred early and
managed in a reference centre with immediately available surgical facilities.
Patients with uncomplicated IE can be initially managed in a nonreference centre, but with regular communication with the reference centre,
consultations with the multidisciplinary Endocarditis Team and, when needed, with external visits to the reference centre.
Characteristics of the reference centre
Immediate access to diagnostic procedures should be possible, including TTE, TOE, multislice CT, MRI, and nuclear imaging.
Immediate access to cardiac surgery should be possible during the early stage of the disease, particularly in patients with complicated IE (HF, abscess,
large vegetation, or neurological and embolic complications).
Several specialists should be present on site (the Endocarditis Team), including at least cardiac surgeons, cardiologists, anaesthesiologists, infectious
disease specialists and microbiologists, and when available specialists in valve diseases, CHD, pacemaker extraction, echocardiography and other
cardiac imaging, and neurologists (together with facilities for neurosurgery and interventional neuroradiology).
Role of the Endocarditis Team
The Endocarditis Team should have meetings on a regular basis to discuss cases, take surgical decisions, and define the type of follow-up.
The Endocarditis Team chooses the type, duration, andmode of follow-up of antibiotic therapy, according to a standardized protocol, following current
guidelines.
The Endocarditis Team should participate in national and international registries, publicly report the mortality and morbidity of their centre, and be
involved in a quality improvement programme (certifications?), as well as in a patient education programme.
The follow-up should be organized on an outpatient visit basis at a frequency depending on the patient’s clinical status (ideally at 1, 3, 6 and 12 months
after hospital discharge, since the majority of events occur during this period).
Reproduced from Rundstrom et al. [5], with permission
CHD congenital heart disease,HF heart failure, IE infective endocarditis, TOE transoesophageal echocardiography, TTE transthoracic echocardiography
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positive [18F]FDG PET/CT scan to diagnostic criteria in-
creases sensitivity without significantly decreasing specificity
[14]. The value of cardiac CT was underlined in the AHA/
ACC guidelines [10] and the ESC guidelines [2]. The ESC
considers that the published data are sufficiently strong and
convincing to propose new criteria (the 2015 ESC Modified
Diagnostic Criteria) including these new imaging techniques
as new criteria for the diagnosis of IE. Three items are added
in the ESC diagnostic criteria (Table 2):
1. The identification of paravalvular lesions by cardiac CT
should be considered as a major criterion.
2. In the setting of the suspicion of PVE, abnormal uptake of
[18F]FDG on PET/CT or WBC on SPECT/CT should be
considered as a major criterion.
3. The identification by imaging of recent embolic events or
infectious aneurysms (silent events) should be considered
as a minor criterion.
Figure 1 presents the proposed ESC diagnostic algorithm
including the 2015 ESC modified diagnostic criteria. The di-
agnosis of IE is still based upon the Duke criteria (blood cul-
tures and echocardiography). However, when the diagnosis
remains doubtful, other imaging techniques should be used,
either for diagnosis of cardiac involvement or for imaging
embolic events.
Cardiac imaging in treatment and follow-up of IE
Indications for surgery in IE may be subdivided into three
categories: haemodynamic, infectious and embolic [2]. The
decision to operate is frequently challenging and must be
discussed on an individual basis using a multidisciplinary ap-
proach, i.e. by the Endocarditis Team. Imaging including
echocardiography, cardiac CT and nuclear imaging, plays a
central role in this decision, along with the clinical
presentation.
Table 2 The 2015 ESC modified criteria for diagnosis of IE
Major criteria
Blood cultures positive for IE Typical microorganisms consistent with IE from
two separate blood cultures
Viridans streptococci




Community-acquired enterococci, in the absence
of a primary focus
or
Microorganisms consistent with IE from
persistently positive blood cultures
Two or more positive blood cultures of blood
samples drawn >12 h apart
or
All of three or a majority of four or more separate
cultures of blood (with first and last samples
drawn ≥1 h apart)
or
Single positive blood culture for Coxiella burnetii
or phase I IgG antibody titre >1:800
Imaging positive for IE
Echocardiogram positive for IE Vegetation
Abscess, pseudoaneurysm, intracardiac fistula
Valvular perforation or aneurysm
New partial dehiscence of prosthetic valve
Abnormal activity around the site of prosthetic valve implantation detected by [18F]FDG PET/CT (only if the prosthesis was implanted
>3 months previously) or radiolabelled WBC SPECT/CTAbnormal activity around the site of prosthetic valve implantation detected by
[18F]FDG PET/CT (only if the prosthesis was implanted for >3 months) or radiolabelled WBC SPECT/CT
Definite paravalvular lesions on cardiac CT
Minor criteria
Predisposition such as predisposing heart condition, or injection drug use
Fever defined as temperature >38 °C
Vascular phenomena (including those detected only by imaging): major arterial emboli, septic pulmonary infarcts, infectious (mycotic)
aneurysm, intracranial haemorrhage, conjunctival haemorrhages, and Janeway’s lesions
Immunological phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor
Microbiological evidence: positive blood culture but does not meet a major criterion as noted above or serological evidence of active
infection with organism consistent with IE
The criteria in green boldface-italic-underlined are the new criteria included in the 2015 guidelines
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In summary, the 2015 ESC guidelines on the management
of IE provide a novel approach in the diagnosis and manage-
ment of this life-threatening disease. However, they are main-
ly based on expert opinion because of the low incidence of the
disease, the few available randomized trials and the limited
number of meta-analyses. The sensitivity of the Duke criteria
can be improved by new imaging modalities (MRI, CT, PET/
CT, SPECT/CT) that allow the diagnosis of embolic events
and cardiac involvement when transthoracic echocardiogra-
phy (TTE) or TOE are negative or doubtful. These criteria
are useful, but they do not replace the clinical judgment
reached and agreed by the Endocarditis Team.
Echocardiography for diagnosis of IE
and CIED infections
Echocardiography is still the main diagnostic tool in the as-
sessment of patients with IE [2]. It is essential for diagnosis,
initial evaluation of the risk of complications and the need for
surgery, assessment and monitoring of in-hospital complica-
tions, and morphological and functional assessment of the
patient’s heart condition before hospital discharge.
Diagnosis
TTE should be performed as soon as IE is suspected. TOE
must be performed when TTE is negative and the clinical
suspicion of left-sided IE is high [15]. In patients with an
initially negative echocardiographic examination, TTE and
TOE should be repeated 5–7 days later if the clinical suspicion
of IE remains high [2]. Specific procedural recommendations
for TTE and TOE have been addressed previously [16].
Vegetations are the hallmark lesions of IE, but other echo-
cardiographic findings are also considered major criteria for
the diagnosis of IE; for example, perivalvular abscesses,
perivalvular pseudoaneurysms, intracardiac fistulas, valvular
perforations, valvular aneurysms, and new dehiscence of a
prosthetic valve [2]. The detection of these lesions in patients
with prosthetic valves is more difficult than in patients with
native valves. Currently, the sensitivity of TTE and TOE for
the diagnosis of vegetations is 70% and 96%, respectively, in
native valves and 50% and 92%, respectively, in prosthetic
valves. Regarding abscesses, the sensitivity of TTE is about
50%, compared with 90% for TOE [2, 15]. The specificity for
the detection of abscesses is higher than 90% with both echo-
cardiographic modalities. Therefore, when IE is suspected in
patients with prosthetic valves, both TTE and TOE must be
done systematically.
It is worth emphasizing that the detection of a new large
peri-prosthetic dehiscence should be considered a major crite-
rion of IE even in the absence of other clinical signs or echo-
cardiographic findings of IE [2].
TOE must always be performed when there is clinical sus-
picion of IE in prosthetic valve or CIED carriers [2]. In these
patients, TOE is also clearly superior to TTE in the detection
and sizing of vegetations [16]. TOE allows visualization of
lead vegetations in the right atrium/superior vena cava area
and in other regions less well visualized by TTE. Both echo-
cardiographic modalities are complementary in the assess-
ment of tricuspid valve involvement, and quantification of
tricuspid valve regurgitation and pulmonary hypertension.
Another echocardiographic technique, intracardiac echocardi-
ography, may be considered in patients with suspected CIED
infection, positive blood cultures, and negative TTE and TOE
studies [2].
Fig. 1 Algorithm for the
diagnosis of IE according to the
2015 ESC guidelines (reproduced







include cerebral MRI and/or
whole-body CTand/or FDG PET/
CT or labelled WBC SPECT/CT
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In patients with Staphylococcus aureus bacteraemia, the fre-
quency of IE is high. Therefore, TTE or TOE should be per-
formed according to the patient’s clinical profile and risk fac-
tors for IE [17]. TOE is not mandatory in isolated right-sided
NVE with good quality TTE and clear-cut echocardiographic
findings [18]. Real-time three-dimensional (3D) TOE is useful
for the assessment of vegetation morphology and size, and this
may lead to a better prediction of the embolic risk in IE [19].
This echocardiographic technique is particularly useful in the
assessment of perivalvular extension of the infection, prosthetic
valve dehiscence, and leaflet perforation [20].
It is important to remember that a negative echocardiogra-
phy study (TTE and TOE) does not rule out the diagnosis of
IE. The negative predictive value (NPV) of a second TOE
study in patients with the suspicion of NVE is extremely high.
On the contrary, the NPV of TOE in patients with prosthetic
valves is modest, and in many cases a second diagnostic im-
aging technique will be needed [21].
Initial evaluation of the risk of complications
and need for surgery
The risk in patients with left-sided IE can be formally assessed
according to clinical, microbiological and echocardiographic var-
iables. Early TOE (during the first 48 h after admission) is ad-
visable inmost patients with left-sided IE in order to better assess
vegetation size, degree of valvular regurgitation, and local
perivalvular complications [22]. Patients with periannular com-
plications, severe left-sided valve regurgitation, large vegetations,
severe prosthetic valve dysfunction, low left ventricular ejection
fraction, pulmonary hypertension or premature mitral valve clo-
sure are at highest risk of death, stroke, and the need for surgery
in the active phase of the disease. All these parameters can be
easily and rapidly obtained by echocardiography [23].
Assessment and monitoring of in-hospital
complications
Local infection follow-up should be performed even when the
clinical course of the patient with IE is good. Thus, in order to
monitor vegetation size and to detect new silent complica-
tions, repeated TTE and TOE during in-hospital follow-up
(7–10 days) of uncomplicated IE is recommended [2]. TTE
and TOE must be repeated as soon as a new clinical compli-
cation appears during the patient’s in-hospital clinical course
(new murmur, heart failure, embolism, persisting fever, atrio-
ventricular block).
Echocardiographic assessment before hospital
discharge
TTE is recommended at completion of antibiotic therapy to
assess left ventricular function, pulmonary pressure, and
valvular morphology and function. For better comparison,
TOE is needed during follow-up in some patients (PV carriers,
patients with complex surgery) before hospital discharge. In
patients with CIED infection, TTE before hospital discharge is
also recommended to detect the presence of retained segments
of the pacemaker lead, and to assess tricuspid valve function,
right ventricular function, and pulmonary hypertension. In
addition, TOE after percutaneous lead extraction should be
considered to detect residual infected material and potential
tricuspid valve complications [15].
Radiolabelled white blood cell imaging
for diagnosis of IE and CIED infections
Radiopharmaceutical preparation and acquisition
protocol
WBC can be r ad io l abe l l ed e i t he r w i t h 9 9mTc -
hexamethylpropyleneamine oxime (99mTc-HMPAO, 370–
555 MBq) or with 111In-oxine (10–18.5 MBq), as detailed in
the specific European Association of Nuclear Medicine
(EANM) guidelines [24, 25]. Briefly, the procedure consists
of isolation, radiolabelling and reinjection of autologous
WBC obtained from the patient’s blood (about 50 mL).
Therefore, strict aseptic conditions are required for the label-
ling procedure. During labelling, care should be taken to avoid
damage to leucocytes, as this would result in leakage of the
radioactivity from the cell, adhesion of labelled leucocytes to
the vascular endothelium and loss of motility. To avoid deg-
radation of the radiopharmaceutical and radiation damage to
labelled cells, radiolabelledWBC should be reinjected as soon
as possible, and not later than 1 h after labelling. 99mTc-
HMPAO is generally preferred, because of the better image
quality (higher count statistics and spatial resolution), and
lower radiation exposure (0.011 mSv/MBq of 99mTc-
HMPAO versus 0.36 mSv/MBq 111In-oxine). Patient prepara-
tion is equivalent to that for any other clinical indication. At
least 2 × 108 leucocytes are required to achieve good labelling
efficiency.
The image acquisition protocol includes planar acquisitions
at 30min (early images), 4–6 h (delayed images), and 20–24 h
(late images) after reinjection of 99mTc-HMPAO/111In-oxine
WBC. A SPECT/CT acquisition is mandatory as part of the
standard imaging protocol (as discussed in more detail in the
section Technical issues) and it is usually acquired 4–6 h and/
or 20–24 h after injection. Planar acquisitions will always
include whole-body images (at least at 30 min) and anterior
and posterior views of the thorax and any other region of
interest (i.e. CNS, abdomen) when searching for septic embo-
li. In patients with CIED infection, care should be taken to
ensure that the generator site is included in the field of view,
considering all the possible generator positions (i.e.
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abdomen). Late acquisitions are particularly relevant in car-
diovascular infections since background activity related to
blood pool spill-over strongly hampers the detectability of
lesions. These should be acquired with a “time corrected for
isotope decay” modality as described in the EANM guide-
lines. SPECT/CT performed at 4–6 h provides better image
quality and might be repeated at 20–24 h if planar images (and
SPECT images) at 4–6 h are negative.
A low-dose CT transmission scan is acquired while the
patient continues tidal or shallow breathing, and is used for
attenuation correction (CT-AC) and for colocalization (see
below; on average 0.5–1.0 mSv radiation burden).
Transmission data are reconstructed using filtered back-
projection to produce cross-sectional images. With the avail-
ability of cutting-edge SPECT/CT systems, administration of
contrast medium to perform ce-CT is also feasible, despite the
fact that experience in this specific setting is very limited.
Recently, a study including a small sample of patients com-
pared the diagnostic performance of WBC SPECT acquired
on a conventional (NaI) camera to a cardiac-dedicated high-
sensitivity cadmium-zinctelluride (CZT) camera[26]. Using
111In-oxine-labelled WBC, it has been shown that target-to-
background contrast increases with the CZT camera. This ap-
proach has the advantages of overcoming the limitation of low
count statistics with late acquisitions and reducing image
noise due to better energy resolution. The field of acquisition
of such cameras is limited to the cardiac area, but all-purpose
CZT cameras are becoming commercially available and will
be an attractive solution for late imaging in WBC SPECT.
Patient preparation
Preparation of patients with IE and CIED infection for WBC
scintigraphy follow the general recommendations for any oth-
er nuclear medicine procedure and the general rules for WBC
preparation. The major goals are to minimize tracer uptake in
normal tissues, while maintaining uptake in target tissues.
Because the effect of antibiotics on radiolabelledWBC uptake
is unknown, it is important to be aware of ongoing antibiotic
treatment, but no general recommendation on withdrawal can
currently be made.
Image postprocessing and interpretation criteria
Both CT-AC and noncorrected SPECT images have to be
evaluated in the coronal, transaxial and sagittal planes, as well
as in 3D maximum intensity projection (MIP) cine mode.
Misalignment between emission and transmission data may
generate erroneous correction and thus data misinterpretation.
Careful attention should be paid to quality control to avoid
reconstruction artefacts. Noncorrected SPECT images be-
come significantly important in the presence of prosthetic
valves, generators and electrocatheters due to possible
overcorrection artefacts on SPECT/CT images.
The interpretation of WBC scintigraphy should always be-
gin with a visual quality control performed on whole-body
images and chest planar acquisitions to check for: (1) the ab-
sence of high blood pool activity (suggesting the labelling of a
substantial amount of erythrocytes) hampering interpretation
even on delayed and late acquisitions, (2) liver uptake higher
than spleen uptake, and (3) persistent pulmonary uptake (both 2
and 3 suggestingWBC damage prior to reinjection). The signal
kinetics between the acquisitions at 4–6 h and 20–24 h are
important features for interpretation: any stable or increased site
of uptake (either intensity or size) over time, confirmed on
SPECT/CT, is highly suggestive of infection. Overall pooled
sensitivity and specificity have been reported to be 80–86% and
97–100%, respectively, with an AUC of 0.957 [27, 28]. Such a
high specificity is also maintained in patients with very early IE
[29–32], a clinical setting in which WBC should represent the
imaging modality of choice. Semiquantitative evaluation of
WBC is also feasible, despite the fact that it has been validated
in musculoskeletal infections [33] and no data are currently
available for IE/CIED infections. Figures 2 and 3 show exam-
ples of WBC SPECT/CT imaging in NVE and PVE.
In patients with suspected CIED infection and in patients
implanted with a left-ventricular-assist device, WBC imaging
revealed similar figures with a consistent high specificity
[32–34]. In these studies, WBC SPECT/CT was found to be
able to identify and define the precise anatomical location and
extent of a suspected infection, improving patient management
(Fig. 4). Additionally,WBCSPECT/CTallows the detection of
additional unsuspected extracardiac sites of infection in up to
23% of patients with device-related sepsis [33, 35].
Abnormalities detected on WBC imaging should be local-
ized as precisely as possible on SPECT/CT images since: (1)
their colocalization with a structural abnormality considered
as doubtful on echocardiography will support the hypothesis
of infection, and (2) the localization and extent of the disease,
on prosthetic material particularly, may help guide the surgical
procedure. Localization of the sites of concomitant
extracardiac infection from septic embolism is also possible
on SPECT/CT images, influencing the Duke score and con-
sequently the diagnostic certainty.
Pitfalls and differential diagnosis of IE/CIED infections
with WBC imaging
False-positive WBC imaging findings in IE and CIED infec-
tions have been rarely described. On the other hand, false-
negative scans have been observed in the presence of IE
caused by some strains such as Candida spp. and
Enterococcus spp. possibly due to the ability of these micro-
organisms (as well as others such as Staphylococcus
epidermidis) to form a “biofilm” that results in resistance to
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antimicrobial treatment and escape from the host defence
mechanisms. Additionally, altered neutrophil recruitment at
the primary site of IE by Enterococcus faecalis extracellular
proteases constitutes a further mechanism of innate immune
response impairment. Such mechanismsmight reduce the sen-
sitivity of scintigraphy with radiolabelled leucocytes in pa-
tients with IE. The same limitation has always to be consid-
ered in patients with CIED infection, in particular in the pres-
ence of very small vegetations along the electrocatheter.
Embolisms on WBC imaging might appear either as
areas of increased uptake over time, for example in
brain, lung and soft tissue embolism, or as cold spots,
for example in spleen embolism and spondylodiscitis.
This latter appearance has to be considered nonspecific
for infectious embolism since it might be present in
other benign or malignant conditions. Therefore, despite
the fact that these findings in patients with IE are high-
ly suggestive of septic embolism, they should be con-
firmed by additional diagnostic imaging tests. In addi-
tion, reduced sensitivity has been reported in patients
with small embolisms [29].
[18F]FDG PET/CT for diagnosis of IE and CIED
infections
Patient preparation and acquisition protocol
When [18F]FDG PET/CT is used to diagnose cardiac and
pericardial infection, patient preparation is very important
due to the possible presence of physiological uptake of
[18F]FDG in normal myocardium. Notably, these protocols
differ fundamentally from cardiac viability imaging protocols
in which myocardial glucose uptake is intentionally enhanced
and homogenized by a combination of glucose loading and
insulin. The current Society of Nuclear Medicine and
Molecular Imaging (SNMMI)/American Society of Nuclear
Cardiology (ASNC)/Society of Cardiovascular CT (SCCT)
guidelines recommend preparation with a fat-enriched diet
lacking carbohydrates for 12–24 h prior to the scan, a fast of
12–18 h, and/or the administration of intravenous heparin ap-
proximately 15 min prior to [18F]FDG injection [36].
Fig. 3 99mTc-HMPAOWBC SPECT/CT imaging in a patient with aortic
NVE showing an increase in uptake of the radiopharmaceutical at the
valve site (from left to right coronal, sagittal and transaxial
superimposed (fused) SPECT/CT images)
Fig. 2 99mTc-HMPAOWBC SPECT/CT imaging in a patient with PVE. The emission image (middle) shows an area of increased radiopharmaceutical
uptake which on the superimposed SPECT/CT image (bottom) corresponds to the prosthetic aortic valve. Top low-dose CT image
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A recent review provides a unique overview of the avail-
able literature regarding preparation for cardiac [18F]FDG
PET imaging [37]. The data support the use of a high-fat,
low-carbohydrate (HFLC) diet for at least two meals with a
fast of at least 4 h for optimal suppression of physiological
myocardial glucose utilization. Because there is no single su-
perior patient preparation technique, in each institution image
quality data should be continually evaluated to ensure that
adequate suppression of [18F]FDG is achieved in more than
80% of the scans (Table 3). Finally, following [18F]FDG in-
jection and before the images are obtained, the patient should
continue to fast and should not be physically active, as either
of these will enhance myocardial glucose uptake.
Although antimicrobial treatment is considered to decrease
the intensity of [18F]FDG accumulation [38], there is no evi-
dence at this stage to routinely recommend treatment discontin-
uation before performing PET/CT. On the contrary, steroid treat-
ment should be discontinued or at least reduced to the lowest
possible dose in the 24 h preceding the examination [39].
Blood glucose levels should always be checked and record-
ed, keeping in mind that, in contrast to tumour imaging, nei-
ther diabetes nor hyperglycaemia at the time of the study has
been demonstrated to increase the false-negative rate in pa-
tients with infection or inflammation [40]. Therefore, although
efforts should be made to decrease blood glucose to the lowest
possible level, hyperglycaemia should not represent an abso-
lute contraindication to performing the study [41]. [18F]FDG
imaging can be performed in patients with kidney failure,
although the image quality may be suboptimal and prone to
interpretation pitfalls [42].
The administered activity does not crucially affect the results
of the examination within a certain range and also depends on
the type of PET scanner. The EANM guidelines on [18F]FDG
PET imaging in inflammation/infection suggest a dose of 2.5–
5.0 MBq/kg, that is 175–350 MBq or 4.7–9.5 mCi in a 70-kg
standard adult. In the US, the [18F]FDG administered activity
should be 370–740 MBq (10–20 mCi) in adults and 3.7–
5.2 MBq/kg (0.10–0.14 mCi/kg) in children [43].
Technical issues
The acquisition is usually performed according to routine pro-
tocols, 45–60 min after intravenous injection of [18F]FDG,
with an emission time/bed position depending on the sensitiv-
ity of the scanner. One report suggests that delayed imaging
acquired 3 h after injection (while maintaining the count
Table 3 Recommendations for patient preparation for cardiac
[18F]FDG PET/CT imaging for IE/CIED infections
Recommendation
Intervention
High evidence High-fat no-carbohydrate diet for at least two meals
Fast for at least 4 h prior to examination
Avoid carbohydrate consumption
Optimize fat intake




Heparin given intravenously 15 min before
[18F]FDG with dietary preparation/fasting
Low evidence Any food or drink during the 4 h before the
examination
Unrestricted diet
Isolated fasting (<12 h)
Calcium channel blockers
Adapted from Osborne et al. [37]
Fig. 4 99mTc-HMPAO WBC SPECT/CT images in a patient with
suspected CIED infection showing radiopharmaceutical uptake at the
pocket site (top transaxial images, from left to right low-dose CT,
emission and superimposed SPECT/CT images, respectively) and at the
intracardiac portion of the leads (bottom coronal images, from left to right
low-dose CT, emission and superimposed SPECT/CT images,
respectively)
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statistic by doubling the time per bed position) is associated
with greater contrast and improves the accuracy in diagnosing
pacing lead infections in comparison with the standard proto-
col [44]. However, recently and in a small series of patients
images acquired at late time-points (150min) after injection in
patients with PVE have been found to be more prone to false-
positive interpretation in both visual and semi-quantitative
analyses [45].
The field of acquisition is usually derived from oncol-
ogy studies from the skull base to the mid-thighs.
Cerebral complications are frequent in left-sided IE and
MRI studies have shown that early brain imaging can
affect the diagnosis and management of patients [46].
Due to the low sensitivity of [18F]FDG PET in the detec-
tion of brain lesions, inclusion of the brain in the field of
acquisition is not recommended. A series of case reports
suggest that the extension of the field of acquisition to the
lower limbs allows the detection of complications of IE
such as mycotic aneurysms that may require specific treat-
ment by embolization to prevent rupture [47]. All these
data are preliminary, based on small population samples,
and require further validation.
The majority of PET/CT studies involve the use of a
protocol comprising a scanogram/scout scan/topogram
and CT-AC. Overall, the CT scan parameters should
be such that patient exposure is the minimum necessary
to provide diagnostic information. The simultaneous ac-
quisition of a standard diagnostic CT scan with intrave-
nous contrast agent is possible and should be preferred
when appropriate in order to maximize the diagnostic
information provided by the examination. Different im-
aging protocols might be suggested for a PET/ce-CT
scan (Tables 4 and 5 and Addendum 1).
In a series of patients with suspected PVE or CIED
infection, Pizzi et al. showed that the addition of ce-CT
to the standard [18F]FDG PET/CT protocol results in a
high rate of patients reclassified from “possible” IE to
“definite” IE, thus improving the overall diagnostic ac-
curacy as compared with PET/CT without contrast en-
hancement combined or not with the Duke score [49].
The main additional information provided by ce-CT
was: better discrimination of the origin of FDG uptake
between prosthetic valves or incomplete myocardial sup-
pression; better coregistration between PET and ECG-
gated CT angiography; identification of a greater num-
ber of anatomical lesions in the valve area and of
periannular complications; and the preoperative evalua-
tion of coronary artery disease. Though not recommend-
ed for routine use, ce-CT combined with PET may
prove useful in selected patients, particularly when
echocardiography is of poor quality or did not allow
precise evaluation of the periannular area. Limiting the
wider use of ce-CT is the deleterious impact of contrast
agents on kidney function. Patients with IE or CIED
infection are likely to receive high doses of antibiotics,
some of them nephrotoxic, over long periods of time. It
is therefore crucial to avoid any unnecessary exposure
to additional nephrotoxic agents.
Table 4 Protocol for WBC SPECT/CT
Acquisition time Acquisition
30 min (early) Whole-body and/or planar thorax/upper
abdomen
followed by
4–6 h (delayed images) Planar images of the thorax
followed by
Planar images of any additional FOV
followed by
SPECT/CT acquisitions of the thorax with
patient continuing tidal or shallow breathing
followed by
SPECT/CT acquisitions of any additional FOV
followed by
20–24 h (late images) Planar images of the thorax
followed by
Planar images of any additional FOV
followed by
SPECT/CT if needed
FOV field of view
Table 5 Protocols for [18F]FDG PET/CT and for [18F]FDG PET with
ce-CT
Protocol Acquisitions
1. [18F]FDG PET/CTwhen CT
is used for attenuation correction
and localization only (not




Low-dose CT scan (continuous















diagnostic CT scan [48]
CT topogram
followed by
Thoracic CT in deep inspiration
to acquire images of the
arterial phase
followed by
Whole-body CT in portal phase
followed by
Whole-body PET
a In the case of CT systems with up to six rings, a protocol using breath-
hold in normal expiration is preferred
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Imaging postprocessing and interpretation criteria
It is recommended that reconstructions be performed with and
without attenuation correction to identify potential reconstruc-
tion artefacts. Such artefacts have been well investigated in
CIEDs, including pacing lead artefacts [50, 51]. Metal artefact
reduction techniques are useful for minimizing overcorrection
artefacts, despite not always being successful in annulling
their impact on PET image quality. The CT data acquired
during the PET/CT study are usually reconstructed using fil-
tered back projection. Recently introduced iterative recon-
struction methods for CT data may be applied, if available
on the PET/CT system. Depending on the CT protocol and
the clinical case, separate CT reconstructions may be per-
formed for diagnostic purposes.
PET images have to be visually evaluated for increased
[18F]FDG uptake, taking into consideration the pattern (focal,
linear, diffuse), intensity and relationship to areas of physiolog-
ical distribution. PET information is compared with morpho-
logical information obtained by CT (Figs. 5 and 6). Several
recent meta-analyses have indicated that the overall pooled
sensitivity of [18F]FDG PET/CT in IE is 61% [1], increasing
to 73%when only PVE are considered and to 76% [27] or 81%
with good overall accuracy (AUC 0.897) [28] when including
only studies reporting adequate cardiac preparation. Thus, even
if the PET results are negative (including whole-body evalua-
tion for embolism detection), thorough interpretation of the
echocardiography and CT scan is essential.
The pooled specificity of [18F]FDG PET/CT in patients
with adequate cardiac preparation has been reported to be be-
tween 85% and 90% [27, 28]. Indeed. in the absence of infec-
tion, [18F]FDG uptake around the prosthetic valve might be
visible particularly early after surgery, and has different causes.
Faint and homogeneous [18F]FDG uptake strictly limited to the
Fig. 5 Examples of different patterns of 99mTc-HMPAO WBC and
[18F]FDG uptake in patients with confirmed PVE: a typical focal
pattern at 99mTc-HMPAO WBC imaging; b focal pattern of [18F]FDG;
c diffuse [18F]FDG uptake of; d focal uptake over an area of diffuse
[18F]FDG uptake. From left to right transaxial emission, low-dose CT
and superimposed SPECT/CT or PET/CT images
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valve annulus or around the struts of a bioprosthetic valve, very
similar to the pattern observed in prosthetic vascular grafts
[52], is most likely to have resulted from a persistent host
reaction against the biomaterial coating the sewing ring of
the prosthetic valve and chronic tension or friction exerted on
these anchor points [53, 54]. Such [18F]FDG uptake seems to
be slightly greater in mechanical than in biological prostheses
and in patients with vasculitis [55]. To prevent misinterpreta-
tion of a positive scan due to imaging too early after valve
implantation, the ESC guidelines recommend that [18F]FDG
PET results should not be considered in the 3-month period
following prosthetic valve implantation [2]. However, if sur-
gery was uncomplicated, imaging before the recommended
3 months might be considered in an individual patient with
awareness of this possible limitation [55].
In patients with NVE, interpretation of [18F]FDG uptake
when the HFLC diet has been successfully adhered to is more
straightforward than in those with PVE since any focal
[18F]FDG uptake should be considered as abnormal. However,
the diagnostic value of [18F]FDG PET in patients with NVE has
not been well determined, due to higher rates of patients with
prosthetic valves or mixed patients with native and prosthetic
valves included in most studies. Recently, Granados et al. found
that [18F]FDG PETwas negative in six of six patients diagnosed
with definite NVE [56]. In a recent meta-analysis pooled sensi-
tivity for NVE was 71% [27]. The lack of sensitivity of
[18F]FDG PET in NVE is probably related to: (1) the size of
the lesion (NVE is generally limited to the presence of a vege-
tation, whereas in PVE generally spreads along the sewing ring
or leads to abscess formation), and (2) the fact that blurring
artefacts due to motion are more important at the tip of a valve
leaflet than at the annulus. In this regard, ECG-gated acquisi-
tions could help. This further emphasizes the need for a
multimodality approach in which each imaging modality over-
comes the other’s possible limitations in this clinical setting.
Semiquantitative analysis using the standardized uptake
value (SUV) is also possible. However, in contrast to its ap-
plication in oncology, SUV has not been validated in inflam-
mation and infection. The additional value of quantitative pa-
rameters (SUVmax normalized or not to the blood pool activ-
ity, referred to as the target-to-background ratio) in differenti-
ating between infected and non-infected material is a matter of
debate. Whereas some literature tentatively provides values
likely to identify infection with high specificity, it seems that
the overlap of SUV between infected and non-infected pros-
thetic valves precludes determination of a threshold. In this
regard, all the factors influencing SUV quantification should
be carefully considered, including those related to patient
preparation (glycaemia, concurrent treatment, etc), time of
uptake and the use of positive contrast.
The value of [18F]FDG PET in the diagnosis of CIED in-
fection is substantiated by a large body of literature. After some
Fig. 6 Same patient as in Fig. 5c. In addition to the diffuse uptake of mild
intensity at the valve prosthesis (a from left to right transaxial emission,
superimposed PET/CT, low-dose CT and ce-CT images), combined
[18F]FDG PET/CT with ce-CT allows the identification of spleen
embolism as shown on both the PET/CT and ce-CT images (b from left
to right transaxial emission, superimposed PET/CT, low-dose CTand ce-
CT images), and brain embolism as shown only on the ce-CT images (c,
ce-CT transaxial image)
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case reports and the seminal work of Ploux et al. [57], a larger
scale study compared three groups of patients implanted with
CIEDs: patients with suspicion of device infection, patients
with a recently implanted device, and a control group of pa-
tients without infection [58]. Images without attenuation cor-
rection were used for final interpretation and to determine a
parameter referred to as the semiquantitative ratio (SQR; the
maximum count rate of the pocket device divided by the mean
count rate of the lung parenchyma). The study showed the
presence of mild postoperative residual inflammation up to
2 months after device implantation, whereas infected devices
showed a significantly greater SQR. Both the sensitivity and
specificity were >85% in a population with a high prevalence
of infection. Finally, those patients with suspicion of infection
but without [18F]FDG uptake had a favourable outcome under
antibiotic therapy, suggesting the absence of bacterial coloni-
zation of the CIEDs. It is noteworthy that no abnormal uptake
was detected in the control group. A prospective study further
supported the value of SQR for diagnosing CIED infection,
and suggested that this parameter could help identify patients
requiring device extraction [59]. More recently, normalization
of SUVmax around the CIED to the mean hepatic blood pool
activity has been shown to be an accurate and consistent quan-
titative parameter for discriminating infected from asymptom-
atic and symptomatic non-infected devices. In the same study,
however, no significant differences were found between sev-
eral different SQRs with the exception of the contralateral ref-
erence region that showed the lowest values. Metabolic uptake
was increased at later acquisition time-points (90 and 180min),
suggesting potential usefulness of delayed imaging in terms of
visual assessment and increasing reporter confidence [60].
Recent meta-analyses have shown a pooled sensitivity of
[18F]FDG PET/CTof 83–87% and a pooled specificity of 89–
94%. These values were higher for generator/pocket infec-
tions (93–96% and 97–98%, respectively) than for infections
at the side of electrocatheters, where they were 65–76% and
83–88%, respectively [27, 61, 62], as a consequence of the
very small size of the vegetations along the leads, which are
often smaller than the spatial resolution of the system [57].
Therefore, [18F]FDG PET/CT has been suggested to be of
value in guiding the clinician in choosing the most suitable
treatment, i.e. conservative treatment (antimicrobial agents
alone, or removal of just the generator) versus device removal.
This is especially relevant considering the ongoing debate
concerning the observation that novel antimicrobial agents
can penetrate the bacteria-produced biofilm [63], thus poten-
tially decreasing the need of hardware removal in CIED infec-
tion [64]. However, considering that the differential diagnosis
between an infection limited to the skin/pocket and more se-
vere infection that involves the device over the pocket is the
clue to choosing medical or surgical treatment in CIED infec-
tion, further investigation is needed before [18F]FDG PET/CT
can be introduced into the routine diagnostic work-up to guide
such a clinical decision. Figure 7 shows an example of
[18F]FDG PET/CT in a patient with CIED infection.
One of the main features of [18F]FDG PET/CT is the ability
to perform whole-body evaluation for abnormal focal uptake of
[18F]FDG in a single scan with very high sensitivity [65]. In the
setting of IE/CIED infection, the detection of septic emboli
affects the Duke score and consequently the diagnostic certain-
ty [44, 56, 65–69]. This comprehensive evaluation of the dis-
ease extent will affect therapeutic management and lead to a
reduction in the risk of relapse [59, 70]. This has been shown to
be particularly useful in the identification of embolisms in un-
expected locations, such as mycotic aneurysms [47], a potential
life-threatening complication requiring specific treatment.
Similarly, in right-sided IE or CIED infection the detection of
lung embolisms, considered as a major criterion of the Duke
score, increases the diagnostic sensitivity [71]. In addition,
identification of the infection portal of entry on [18F]FDG
PET/CT is critical to prevent IE relapse. This primary infectious
site may be orientated by the common biotope of the bacteria
strain (digestive, skin, catheter) and should be part of the report.
Finally, an additional promising role of [18F]FDG PET/CT
is in patients with established IE, in whom it can be used to
monitor response to antimicrobial treatment. Indeed, consider-
ing the difficulties in the choice of type, dose and duration of
antimicrobial treatment, the possibility of using PET/CT imag-
ing to distinguish between patients who respond favourably to
treatment from those who require intensified administration or
alternative treatment options is extremely attractive. However,
significant data in this regard are scarce and the use of PET/CT
in this clinical scenario can be suggested only as part of a case-
based discussion within the Endocarditis Team.
Pitfalls and differential diagnosis of IE/CIED infections
with [18F]FDG PET/CT
As discussed in detail, the diagnostic performance of
[18F]FDG PET in IE and CIED infections is highly dependent
on the background activity from physiological [18F]FDG
myocardial uptake, and accordingly on the correct adherence
to the HFLC diet followed by a fast of >12 h as discussed
above in more detail. This is critical for the optimal analysis of
valvular regions. Another potential confounding factor for
[18F]FDG PET/CT is increased metabolic activity along the
posterior part of the heart, where lipomatous hypertrophy of
the interatrial septum may appear as a fat-containing mass
with increased [18F]FDG uptake [72]. Early PET/CTscanning
following valve implantation is not recommended since per-
sistent reaction of the host against the synthetic component of
the sewing ring might cause false-positive results. The persis-
tent host reaction against the biomaterial coating of the sewing
ring of the prosthetic valve may persist for years after valve
implantation and should always be considered as a source of
misinterpretation.
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A wide range of pathological conditions can mimic the
pattern of focally increased [18F]FDG uptake. The follow-
ing conditions might present with focal [18F]FDG uptake:
active thrombi [73], soft atherosclerotic plaques [74], vas-
culitis [75], primary cardiac tumours [76] and cardiac me-
tastasis [77], postsurgical inflammation [78] and foreign
body reactions (such as a reaction to BioGlue, a surgical
adhesive used to repair the aortic root) [79], and stitches
[80]. Recently intense [18F]FDG uptake has also been
found in a patient with Libman-Sacks endocarditis [81].
Therefore, to maintain the high specificity of [18F]FDG
for IE, it is essential that patient selection and inclusion
criteria, as well as image reading, are accurate. In this
regard, the CT component of PET/CT plays a crucial role
by accurately localizing vascular wall uptake and intracar-
diac lesions.
Fig. 7 99mTc-HMPAO WBC (a) and [18F]FDG PET/CT (b) in patients
with CIED infection. Faint WBC uptake is prentent at the pocket site
which is an artifact due to attenuation correction as demonstrated by the
disappearnce of the uptake at the non-attenuated corrected images(a
upper panel from left to right transaxial emission, superimposed
SPECT/CT and non-attenuated corrected), whereas the uptake at the
intracardiac portion of the leads, is consistent with infection (lower
panel, coronal view emision and fused SPECT/CT). In b increased
[18F]FDG uptake at both the pocket site and at the intravascular portion
of the leads, persisten at the non-attenuated corrected images (upper, from
left to right transaxial emission, superimposed PET/CT and non-
attenuated corrected) and at the intracardiac portion of the leads (lower
panel from left to right coronal emissiona nd fused PET/CT) confirming
the presence of device infection. From left to right transaxial images and
coronal images emission, low-dose CT, superimposed PET/CT and non-
attenuated emission images, respectively
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As already discussed, antimicrobial therapy and/or veg-
etation size can account for false-negative [18F]FDG PET/
CT results.
Cardiac CT for diagnosis of IE and CIED
infections
Since the introduction of the first 64-slice CT devices in 2005,
cardiac CT has evolved to be one of the most important struc-
tural imaging techniques of the heart. Its strengths lie in the
high isotropic (i.e. in all three axes of 3D space) spatial reso-
lution in the range of 0.2 to 0.3 mm with the most recent
devices, and its ease of use and wide availability. The draw-
backs of cardiac CT are the need for iodinated contrast agent
administration and ionizing radiation. The latter, however, can
be limited with appropriate imaging protocols and newer de-
vices to a radiation dose in the low single-digit millisievert
range (depending on the field of view). Temporal resolution
has also been improved considerably (from 250 ms with the
first generation four-slice CTscanners down to 66 ms with the
most recent dual-source devices), allowing high-quality im-
ages to be obtained in patients with faster heart rates or even in
selected patients with rate-controlled atrial fibrillation [82].
In the context of IE and CIED infections, cardiac CT may
serve two different purposes. First, cardiac CT almost invari-
ably complements every radionuclide imaging study (e.g.
[18F]FDG PETorWBC scintigraphy) to provide an anatomical
map for coregistration with radionuclide signals. This allows
identification of the particular anatomical structures with path-
ological uptake and improves the diagnostic accuracy of the
technique. Most often, this objective is achieved with a native
low-dose CT scan, although some have suggested that
performing ECG-gated ce-CT angiography may improve the
diagnostic accuracy of the combined hybrid study (as men-
tioned before) [83]. Second, the anatomical information pro-
vided by CT may itself allow the diagnosis of IE or CIED
infection, particularly in the presence of vegetations and com-
plications such as abscesses, pseudoaneurysms, fistulas or sep-
tic embolization. Moreover, cardiac CT, if performed on a
high-end CT device, allows the assessment of coronary arteries
prior to any surgical procedure. This avoids preoperative inva-
sive coronary angiography, which (in the case of aortic valve
endocarditis) carries a certain risk of vegetation embolization
due to manipulation of the catheter in the aortic root [84].
Patient preparation
Only minor patient preparation is required prior to cardiac CT.
In fact, cardiac CToffers the advantage of also being available
for urgent indications or in critically ill patients. The level of
patient preparation depends solely on the type of scan envis-
aged, and the latter in turn depends on the clinical situation
and the question of interest. In the simplest case, where only a
native (noncontrast) nongated CT scan is required (e.g. for
simple coregistration with radionuclide imaging according to
a standard PET/CT protocol), no particular patient preparation
is needed. The scan is usually performed immediately before
or after the acquisition of PET emission data. Occasionally,
however, if indicated for IE and/of CIED infection, a high-
resolution contrast-enhanced ECG-gated scan will be pre-
ferred to resolve anatomical details of moving heart structures.
In this case, it is generally recommended that the patient
should fast for 3–4 h prior to the scan [85]. A careful history
with regard to potential pregnancy, allergy to contrast agents,
and impaired renal function should be taken.
Despite the high temporal resolution of current CT devices,
image quality still depends considerably on heart rate. In pa-
tients with heart rates >65 bpm, pretreatment with a beta-
receptor antagonist (either intravenously or orally depending
on the clinical setting) is recommended to lower the heart rate
as much as possible, preferably below 60 bpm, providing there
is no contraindication to the use of these agents [85]. Although
achieving diagnostic quality for the assessment of coronary
arteries may not be the primary goal of the scan, it may still
be advisable to lower the heart rate and administer nitrates prior
to image acquisition. Special care should be taken in patients
with severe aortic regurgitation, in whom lowering the heart
rate may have detrimental haemodynamic effects.
Imaging protocols and technical issues
As mentioned above, different image acquisition protocols
may be used depending on the scanner platform and the
type of scan ordered. To obtain high-quality images in re-
gions affected by cardiac motion, ECG gating by either
retrospective or prospective triggering is indispensable.
Retrospective gating offers the advantage of allowing re-
construction of CT images over all phases of the cardiac
cycle. This allows the demonstration of the oscillation of
masses, visualization of native or prosthetic valvular func-
tion, and identification of rocking motion in prosthetic dys-
function. However, the radiation dose is considerably
higher with retrospective ECG triggering (depending on
scan parameters and the use or not of dose-modulation
algorithms, up to 20 mSv). On the other hand, prospective
ECG gating triggers image acquisition during a predefined
interval of the RR cycle and therefore is obtained with a
fraction of the exposure radiation of retrospective helical
scans. Radiation dose also depends on the longitudinal
field of view of the scanner and is higher for partial-body
CT angiography than for cardiac CT angiography. High-
end CT devices with 64 slices or more are generally pre-
ferred due to their higher spatial resolution, larger axial
coverage and shorter scan time. Good quality images are
difficult to obtain in patients with atrial fibrillation or
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tachycardia due to the deleterious effect on image quality
of motion artefacts. In these patients, it is recommended
that the heart rate is lowered as much as possible using oral
or intravenous beta-blockers (if clinically feasible) and that
devices with the highest temporal resolution are used (e.g.
dual-source scanners, if available).
Imaging postprocessing and interpretation criteria
Images are generally reconstructed as transaxial images,
multiplanar reformations, maximum intensity projections, and
3D volume renderings. For fusion with radionuclide images,
axial and coronal source images are usually the preferred mode
Fig. 9 Same patient as in Fig. 8. a
Double-oblique multiplanar
reformatted cardiac CT image
shows a perivalvular abscess
(arrowheads) surrounding the
entire aortic root (Ao) with the
largest collection between the left
atrium (LA) and the left coronary
cusp. b 3D volume-rendered CT
image shows the relationship
between the pseudoaneurysm
(arrowheads) and the other
anatomical structures: The
pseudoaneurysm is located just
anterior of the left main coronary
artery (LMA) but does not
compromise the vessel. c
Transoesophageal
echocardiography (TOE) image
shows a hypoechogenic abscess
between the aortic root and the
left atrium. d The colour Doppler
image confirms the presence of at
least two small perforations of the
left coronary cusps (white arrows,
yellow arrows in c) which are not
clearly visible on the CT image
(yellow arrow in a)
Fig. 8 A 52-year-old man with prosthetic aortic valve endocarditis
(coagulase-negative staphylococci) 4 years after aortic root replacement
with a 25-mm Freestyle biological valve, replacement of the ascending
aorta with a 28-mmDacron graft and reconstruction of the posterior sinus
with xenopericardium. a ECG-gated contrast-enhanced cardiac CT image
(GE VCT 64-slice CT scanner) of the aortic root (Ao) shows a
pseudoaneurysm of the left coronary sinus (arrowheads) with a small
3–4 mm vegetation (yellow arrow) attached to the anterior aspect of the
neck of the pseudoaneurysm. b Transoesophageal echocardiography
(TOE) image confirms the CT findings. Note that the CT and TOE
images have opposite anteroposterior orientation (LA left atrium, RCA
right coronary artery)
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of display. Multiplanar reformations of ce-CT images allow
reconstruction of the structure of interest in every possible
plane, and thereby allow assessment of its structure, size and
extent. Vegetations appear as irregularly shaped, hypodense,
oscillating structures adherent to the endocardium (Fig. 8).
Abscesses are defined as irregularly shaped, inhomogeneous
masses within the paravalvular myocardium or pericardium,
while a pseudoaneurysm is defined as space filled with contrast
medium with connection to any of the cardiac chambers (Fig.
9). CT has shown very high sensitivity in comparisonwith TOE
or surgery in detecting the presence and extent of paravalvular
complications such as abscesses and pseudoaneurysms [86,
87]. TOE, on the other hand, is probably superior to CT for
the diagnosis of small vegetations and for detecting leaflet per-
forations, particularly if they are smaller than 2 mm (Fig. 9).
However, in the setting of PVE, the diagnostic yield of TOE
is lower than in NVE as previously mentioned. In PVE, the
onset of infection may be more insidious, extension of infec-
tion into the perivalvular tissue more common, and acoustic
shadowing from metallic prostheses interferes with TOE im-
aging (particularly in the detection of paravalvular complica-
tions located in or close to the right coronary cusp). In this
setting, CT may even be superior to TOE in detecting vegeta-
tions, abscesses, and pseudoaneurysms [88]. TOE remains
more sensitive than CT for valvular dehiscence, although using
retrospective ECG triggering and image reconstruction at dif-
ferent time intervals during the RR cycle after a full helical CT
scan, even rocking motion from a severely detached prosthesis
can be visualized. However, large comparisons between CT
and TOE are lacking, therefore CT and TOE are considered
complementary techniques, but it is recommended that TOE
remain the first-line test in suspected PVE. Moreover, CT al-
lows the assessment of systemic complications from IE includ-
ing septic embolization (e.g. lung, spleen, brain), mycotic an-
eurysms, and intracranial bleeding, which may all have impor-
tant implications for patient prognosis and management and
may add to the diagnostic criteria for IE.
In recognition of the increasing role of cardiac CT, the 2015
ESC guidelines for the management of IE have been modified
by adding to the traditional Duke criteria “definite para valvu-
lar lesions by cardiac CT” as a major criterion, and “vascular
phenomena detected by CT including arterial emboli, septic
pulmonary infarcts, infectious (mycotic) aneurysm, intracra-
nial haemorrhage, conjunctival haemorrhages, and Janeway’s
lesions” as a minor criterion for endocarditis [2].
In CIED infections, cardiac CT probably has a more limited
role than radionuclide imaging, except for providing anatomical
maps to coregister signal from radionuclide imaging with ana-
tomical structures (e.g. device pocket or leads). In the majority
of cases, nongated native CT scans are considered sufficient for
this purpose. Small vegetations on pacemaker leads may be
difficult to detect on ce-CTangiography and the generator often
causes significant blooming and beam hardening artefacts in
the pacemaker pocket. However, as mentioned before in the
field of IE, CT angiography may add important remote infor-
mation on vascular complications such as mycotic aneurysms,
arterial emboli, and septic pulmonary infarcts, which adds to the
diagnostic criteria and affect the overall treatment strategy.
Pitfalls, differential diagnosis of IE/CIED infections
with CT
Even though CT has been demonstrated to be more accurate in
the presence of metallic prostheses, it is not devoid of artefacts.
Some tilting-disc metallic prostheses, such as the Björk-Shiley
valve, have been associated with severe beam-hardening arte-
facts, which affect the correct evaluation of the perivalvular
region [89]. Increased wall thickness of the aorta has been pro-
posed as a sign of early aortic root infection after surgery.
However, there is no consensus about the upper limits of the
normal aortic root thickness after aortic valve surgery. In addi-
tion, in the early postoperative period, the aortic wall may be
thickened from haematoma or oedema,whichmay resolvewith-
in 3 to 6 months, requiring close imaging follow-up and inte-
gration of clinical findings. The differential diagnosis of valvular
vegetations includes mobile strands or free sutures arising from
sewing rings or prosthetic valves, and cardiac (mostly benign)
masses such as thrombus, fibroelastoma and myxoma.
The “imaging specialist” in the Endocarditis
Team: role, challenges and education
The newESC guidelines for themanagement of IE introduce the
Endocarditis Team as the basis for maximizing the likelihood of
success in managing patients with IE and CIED infections. They
delineate the wide scope and complexity of the Endocarditis
Team and provide a general framework for its functioning, in-
cluding recommending the professionals who should be in-
volved in the decision making process. Given the complexity
of the topic, a team approach provides the most logical solution
to delivering interdisciplinary competence. The benefits of team-
work are obvious. The team approach leads professionals to
evaluate IE as a whole complex, multisite disease that should
be addressed with an integrated diagnostic-therapeutic strategy
rather than a single isolated medical action. The diverse range of
professionals working together, bringing together diverse
knowledge and skills, results in higher levels of innovation in
patient care and faster decision making. From the patients’ (and
also the families’) perspective, teamwork affects compliance
since it is easier to communicate with a cohesive team than with
practitioners who work in isolation.
Efficient team functioning is challenging. Building well-
functioning teams requires time, education and support. With
time, team members get to know each other and learn about
each other’s professional work and attitudes to change and
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innovation. More time is necessary to allow team meetings to
discuss patient and programme issues. Yet time for education, a
complex issue that requires a shared team vision to improve
specific medical knowledge and skills to accomplish team de-
velopment, has to be planned. The “Imagers” are called to play
a more and more active role in the team programme and in the
global educational planning. With evolving technologies, the
choice of investigation and the interpretation of results have
become more complex. Therefore teamwork serves as an im-
portant opportunity to update professional knowledge and for
continuing professional development. With this changed way
of thinking, the team can effectively collaborate and ultimately
provide the best care to the patients so that they receive the
proper diagnosis and treatments [90]. Locally available re-
sources might be critical and it may seem impossible to fit more
time for working with the team into the competing priorities of
healthcare and educational professionals. But the time spent
working on more effective approaches may actually save time
in the long run. A quotation from Henry Ford seems apt: “com-
ing together is (just) the beginning of the process”. For this
issue, strong joint educational initiatives are needed to set a
European standard for competency in the practice of imaging.
Conclusions
The Endocarditis Team is a rapidly emerging concept that aims
to provide the most appropriate management of patients with IE
or CIED infections. The team should include cardiologists, car-
diovascular surgeons, specialists in infective diseases or clinical
microbiologists, imagers such as echocardiographists, radiolo-
gists and nuclear medicine physicians. Accordingly, the ESC
has recently published new guidelines on IE in collaboration
with representatives of other disciplines. Imaging is included In
these new guidelines as central in the diagnostic algorithm.
Therefore, imaging procedures have moved from an extempora-
neous procedure used in selected patients and in selected centres
to a widely available method with specific clinical indications. In
these guidelines we aim to provide detailed information on stan-
dardized imaging acquisitions and reporting in patients with
suspected IE or CIED infections, based on consensus agreement
among a wide panel of experts from several disciplines. This
document will help professionals in the management of patients
with IE and CIED infections, strengthen multidisciplinary col-
laboration to provide better healthcare and reduce costs by help-
ing to avoid unnecessary or wrongly executed diagnostic exam-
inations. Even if multimodality imaging is changing the face of
endocarditis diagnosis and management, and is now included in
the ESC guidelines, it is important to re-emphasize:
– The need for specific expertise in reference centres
– The existence of a long and specific learning curve for
each technique
– The need for interpreting imaging data taking into ac-
count the clinical presentation and the advice of the
Endocarditis Team
– The need for additional future registries and studies to pro-
spectively validate the use of multimodality imaging in IE
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